South Korean vaccine developer SK Bioscience Co Ltd is expected to raise 1.5 trillion won ($1.33 billion) in the country’s largest IPO since 2017, after pricing the listing at the top of an indicative range, it said on Monday.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
